Postoperative Myocardial Injury and Inflammation is Not Blunted by a Trial of Atorvastatin in Orthopedic Surgery Patients
Authors:
- 13 October 2017
- journal article
- research article
- Published by SAGE Publications in HSS Journal®: The Musculoskeletal Journal of Hospital for Special Surgery
- Vol. 14 (1) , 67-76
Abstract
Background: Orthopedic patients are at risk for adverse postoperative cardiovascular outcomes. Questions/Purposes: This pilot randomized controlled trial (RCT) of atorvastatin vs. placebo in orthopedic surgery patients was performed in order to assess: (1) the prevalence of perioperative myocardial injury; (2) the effect of atorvastatin on perioperative inflammation; and (3) the feasibility of performing a large RCT of statin therapy in orthopedic patients. Methods: Hip fracture (hip Fx) and total hip and knee replacement (THR and TKR) patients were randomized 1:1 to atorvastatin 40 mg daily vs. placebo, starting preoperatively and continuing until postoperative day (POD) 45. High-sensitivity cardiac troponin I (hs-cTnI), high-sensitivity C-reactive protein (hs-CRP), and interleukin-6 (IL-6) were measured preoperatively and on POD 2. Patients were monitored for adverse events until POD 90. Results: Five hundred fifty-six patients were screened, 22 were recruited (4 hip Fx, 11 THR, 7 TKR), and 2 withdrew. Most (80%) had detectable hs-cTnI (> 1.1 pg/mL) preoperatively. Twenty percent had a perioperative rise in hs-cTnI (≥ 10 pg/mL), which was not blunted by atorvastatin. Hs-CRP rose in 19/20 patients, and IL-6 rose in all patients. However, atorvastatin did not blunt the rise in these inflammatory biomarkers. On POD 2, IL-6 and hs-cTnI levels correlated ( ρ = 0.59, p = 0.02). Recruitment was limited by the high prevalence of statin use in the screened population and a high prevalence of exclusions among hip fracture patients. Conclusion: Perioperative myocardial injury and inflammation are common in orthopedic patients and do not appear to be reduced in those randomized to atorvastatin. Trial Registration: NCT02197065Keywords
Funding Information
- Pfizer Foundation
- Abbott Laboratories
- Weill Cornell Clinical & Translational Science Center (UL1TR000457-06)
This publication has 50 references indexed in Scilit:
- Symptomatic venous thromboembolism and mortality in orthopaedic surgery – an observational study of 45 968 consecutive proceduresBMC Musculoskeletal Disorders, 2013
- Statins, inflammation and deep vein thrombosis: a systematic reviewJournal of Thrombosis and Thrombolysis, 2012
- The pro- and anti-inflammatory properties of the cytokine interleukin-6Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- Evidence of Pre-Procedural Statin TherapyJACC, 2010
- C‐reactive protein lowering with rosuvastatin in the METEOR studyJournal of Internal Medicine, 2010
- Medical Treatment Predicts Mortality After Hip FractureThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2009
- A Randomized Trial of Rosuvastatin in the Prevention of Venous ThromboembolismNew England Journal of Medicine, 2009
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- In-hospital Complications and Mortality of Unilateral, Bilateral, and Revision TKA: Based on an estimate of 4,159,661 DischargesClinical Orthopaedics and Related Research, 2008
- Circulating Cytokines after Hip and Knee Arthroplasty: A Preliminary StudyClinical Orthopaedics and Related Research, 2008